BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value Health 2022;25:59-68. [PMID: 35031100 DOI: 10.1016/j.jval.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schöttler MH, Coerts FB, Postma MJ, Boersma C, Rozenbaum MH. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. Value Health 2022:S1098-3015(22)02044-7. [PMID: 35933271 DOI: 10.1016/j.jval.2022.06.007] [Reference Citation Analysis]